Astrazeneca asset swap kickstarts Innate's independence
Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.
Gamma-delta follows financing with consolidation
A new cell therapy approach has, in low-key fashion, attracted financing and the attention of big biopharma.
Asco 2018 event analyser – A year of reset expectations
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.
